Behandling av ångestsyndrom - SBU

ined paroxetine and clonazepam treatment
strategies compared to paroxetine
monotherapy for panic disorder. J Psychopharmacol
2003;17:276-82.
198. Pollack MH, Worthington JJ, 3rd,
Otto MW, Maki KM, et al. Venlafaxine
for panic disorder: results from a doubleblind,
placebo- controlled study. Psychopharmacol
Bull 1996;32:667-70.
199. Pols H, Zandergen J, de Loof C,
Fernandez I, Griez E. Clinical effects of
fluvoxamine on panic symptomatology.
Acta Psychiatr Belg 1993;93:169-77.
200. Power KG, Sharp DM. Keep taking
the tablets? Inadequate controls for concurrent
psychotropic medication in studies of
psychological treatments for panic disorder.
J Psychopharmacol 1995;9:71-2.
201. Pyke RE, Greenberg HS. Doubleblind
comparison of alprazolam and adinazolam
for panic and phobic disorders.
J Clin Psychopharmacol 1989;9:15-21.
202. Rapaport MH, Pollack MH,
Clary CM, Mardekian J, Wolkow R. Panic
disorder and response to sertraline: the effect
of previous treatment with benzodiazepines.
J Clin Psychopharmacol 2001;21:104-7.
203. Rapaport MH, Wolkow R, Rubin A,
Hackett E, et al. Sertraline treatment of
panic disorder: results of a long-term study.
Acta Psychiatr Scand 2001;104:289-98.
204. Ravaris CL, Friedman MJ, Hauri PJ,
McHugo GJ. A controlled study of alprazolam
and propranolol in panic-disordered
and agoraphobic outpatients. J Clin Psychopharmacol
1991;11:344-50.
205. Ribeiro L, Busnello JV, Kauer-
Sant’Anna M, Madruga M, et al. Mirtazapine
versus fluoxetine in the treatment of
panic disorder. Braz J Med Biol Res 2001;
34:1303-7.
206. Rickels K, Schweizer E, Weiss S,
Zavodnick S. Maintenance drug treatment
for panic disorder. II. Short- and longterm
outcome after drug taper. Arch Gen
Psychiatry 1993;50:61-8.
207. Rifkin A, Pecknold JC, Swinson RP,
Ballenger JC, et al. Sequence of improvement
in agoraphobia with panic attacks.
J Psychiatr Res 1990;24:1-8.
208. Rizley R, Kahn RJ, McNair DM,
Frankenthaler LM. A comparison of alprazolam
and imipramine in the treatment of
agoraphobia and panic disorder. Psychopharmacol
Bull 1986;22:167-72.
209. Robinson DS, Shrotriya RC,
Alms DR, Messina M, Andary J. Treatment
of panic disorder: nonbenzodiazepine
anxiolytics, including buspirone. Psychopharmacol
Bull 1989;25:21-6.
210. Rosenbaum JF, Moroz G, Bowden CL.
Clonazepam in the treatment of panic
disorder with or without agoraphobia: a
dose-response study of efficacy, safety, and
discontinuance. Clonazepam Panic Disorder
Dose-Response Study Group. J Clin
Psychopharmacol 1997;17:390-400.
211. Roy-Byrne PP, Dager SR, Cowley DS,
Vitaliano P, Dunner DL. Relapse and
rebound following discontinuation of
benzodiazepine treatment of panic attacks:
alprazolam versus diazepam. Am J Psychiatry
1989;146:860-5.
212. Roy-Byrne PP, Katon W, Cowley DS,
Russo J. A randomized effectiveness trial
of collaborative care for patients with
panic disorder in primary care. Arch Gen
Psychiatry 2001;58:869-76.
213. Roy-Byrne PP, Russo J, Cowley DS,
Katon WJ. Panic disorder in public sector
primary care: clinical characteristics and illness
severity compared with ”mainstream”
primary care panic disorder. Depress Anxiety
2003;17:51-7.
214. Rynn M, Garcia-Espana F,
Greenblatt DJ, Mandos LA, et al. Imipramine
and buspirone in patients with
panic disorder who are discontinuing
long-term benzodiazepine therapy. J Clin
Psychopharmacol 2003;23:505-8.
215. Salkovskis PM, Clark DM,
Hackmann A. Treatment of panic attacks
using cognitive therapy without exposure
or breathing retraining. Behav Res Ther
1991;29:161-6.
216. Sandmann J, Lorch B, Bandelow B,
Hartter S, et al. Fluvoxamine or placebo in
the treatment of panic disorder and relationship
to blood concentrations of fluvoxamine.
Pharmacopsychiatry 1998;31:117-21.
217. Sasson Y, Iancu I, Fux M, Taub M,
et al. A double-blind crossover comparison
of clomipramine and desipramine in the
treatment of panic disorder. Eur Neuropsychopharmacol
1999;9:191-6.
218. Savoldi F, Somenzini G, Ecari U. Etizolam
versus placebo in the treatment of panic
disorder with agoraphobia: a double-blind
study. Curr Med Res Opin 1990;12:185-90.
219. Schmidt NB, Staab JP, Trakowski JH,
Jr, Sammons M. Efficacy of a brief psychosocial
treatment for panic disorder in an active
duty sample: implications for military
readiness. Mil Med 1997;162:123-9.
220. Schmidt NB, Trakowski JH, Staab JP.
Extinction of panicogenic effects of a 35%
CO2 challenge in patients with panic disorder.
J Abnorm Psychol 1997;106:630-8.
221. Schmidt NB, Wollaway-Bickel K,
Trakowski JH, Santiago HT, Vasey M.
Antidepressant discontinuation in the
context of cognitive behavioral treatment
for panic disorder. Behav Res Ther 2002;
40:67-73.
222. Schmidt NB, Woolaway-Bickel K,
Trakowski J, Santiago H, et al. Dismantling
cognitive-behavioral treatment for
panic disorder: questioning the utility of
breathing retraining. J Consult Clin Psychol
2000;68:417-24.
223. Schwartz RM, Michelson L. Statesof-mind
model: cognitive balance in the
treatment of agoraphobia. J Consult Clin
Psychol 1987;55:557-65.
224. Schweizer E, Fox I, Case G, Rickels K.
Lorazepam vs. alprazolam in the treatment
of panic disorder. Psychopharmacol Bull
1988;24:224-7.
225. Schweizer E, Patterson W, Rickels K,
Rosenthal M. Double-blind, placebo-controlled
study of a once-a-day, sustainedrelease
preparation of alprazolam for the
treatment of panic disorder. Am J Psychiatry
1993;150:1210-5.
226. Schweizer E, Pohl R, Balon R, Fox I,
et al. Lorazepam vs. alprazolam in the
treatment of panic disorder. Pharmacopsychiatry
1990;23:90-3.
227. Schweizer E, Rickels K, Weiss S,
Zavodnick S. Maintenance drug treatment
280 B E H A N D L I N G AV Å N G E S T S Y N D R O M
K A P I T E L 2 • B E H A N D L I N G AV PA N I K S Y N D R O M 281